Ranolazine prevents pressure overload‐induced cardiac hypertrophy and heart failure by restoring aberrant Na+ and Ca2+ handling

Cardiac hypertrophy and heart failure are characterized by increased late sodium current and abnormal Ca2+ handling. Ranolazine, a selective inhibitor of the late sodium current, can reduce sodium accumulation and Ca 2+ overload. In this study, we investigated the effects of ranolazine on pressure overload‐induced cardiac hypertrophy and heart failure in mice.

[1]  Thomas J. Hund,et al.  Ca2+/calmodulin-dependent kinase II-dependent regulation of atrial myocyte late Na+ current, Ca2+ cycling, and excitability: a mathematical modeling study. , 2017, American journal of physiology. Heart and circulatory physiology.

[2]  A. Mugelli,et al.  Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy , 2017, Circulation. Heart failure.

[3]  A. De Angelis,et al.  Long-term administration of ranolazine attenuates diastolic dysfunction and adverse myocardial remodeling in a model of heart failure with preserved ejection fraction. , 2016, International journal of cardiology.

[4]  P. Mohler,et al.  Elevated local [Ca2+] and CaMKII promote spontaneous Ca2+ release in ankyrin-B-deficient hearts. , 2016, Cardiovascular research.

[5]  J. Viola,et al.  Cell cycle and apoptosis regulation by NFAT transcription factors: new roles for an old player , 2016, Cell Death and Disease.

[6]  Sathya D. Unudurthi,et al.  Voltage-Gated Sodium Channel Phosphorylation at Ser571 Regulates Late Current, Arrhythmia, and Cardiac Function In Vivo , 2015, Circulation.

[7]  L. Chi,et al.  Ranolazine Reduces Remodeling of the Right Ventricle and Provoked Arrhythmias in Rats with Pulmonary Hypertension , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[8]  F. Mason,et al.  Late INa increases diastolic SR-Ca2+-leak in atrial myocardium by activating PKA and CaMKII , 2015, Cardiovascular research.

[9]  E. Antman,et al.  Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. , 2015, JACC. Heart failure.

[10]  J. Colombo,et al.  Ranolazine preserves and improves left ventricular ejection fraction and autonomic measures when added to guideline-driven therapy in chronic heart failure , 2014, Heart international.

[11]  Antonio Zaza,et al.  Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension. , 2014, Cardiovascular research.

[12]  D. Fedida,et al.  Ranolazine improves diastolic function in spontaneously hypertensive rats. , 2014, American journal of physiology. Heart and circulatory physiology.

[13]  M. Henein,et al.  Impaired left ventricular systolic function reserve limits cardiac output and exercise capacity in HFpEF patients due to systemic hypertension. , 2013, International journal of cardiology.

[14]  J. Gummert,et al.  Ca2+/Calmodulin-Dependent Protein Kinase II and Protein Kinase A Differentially Regulate Sarcoplasmic Reticulum Ca2+ Leak in Human Cardiac Pathology , 2013, Circulation.

[15]  G. Hasenfuss,et al.  Role of late sodium current as a potential arrhythmogenic mechanism in the progression of pressure-induced heart disease. , 2013, Journal of molecular and cellular cardiology.

[16]  A. Dominguez-Rodriguez,et al.  Ca(2+) fluxes involvement in gene expression during cardiac hypertrophy. , 2013, Current vascular pharmacology.

[17]  M. Michalak,et al.  Coping with endoplasmic reticulum stress in the cardiovascular system. , 2013, Annual review of physiology.

[18]  C. Poggesi,et al.  Late Sodium Current Inhibition Reverses Electromechanical Dysfunction in Human Hypertrophic Cardiomyopathy , 2013, Circulation.

[19]  R. Resende,et al.  Functional Cross-Talk Between Aldosterone and Angiotensin-(1-7) in Ventricular Myocytes , 2013, Hypertension.

[20]  Yi Yang,et al.  MFEprimer-2.0: a fast thermodynamics-based program for checking PCR primer specificity , 2012, Nucleic Acids Res..

[21]  G. Salama,et al.  Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2. , 2012, Heart rhythm.

[22]  L. Maier,et al.  Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. , 2012, Pharmacology & therapeutics.

[23]  Q. Duan,et al.  β-AR Blockers Suppresses ER Stress in Cardiac Hypertrophy and Heart Failure , 2011, PloS one.

[24]  V. Figueredo,et al.  Improvement in Left Ventricular Systolic and Diastolic Performance During Ranolazine Treatment in Patients With Stable Angina , 2011, Journal of cardiovascular pharmacology and therapeutics.

[25]  X. Wehrens,et al.  Transverse aortic constriction in mice. , 2010, Journal of visualized experiments : JoVE.

[26]  M. Sabatine,et al.  B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. , 2010, Journal of the American College of Cardiology.

[27]  U. Schotten,et al.  Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice. , 2009, The Journal of clinical investigation.

[28]  H. Sabbah,et al.  Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. , 2008, American journal of physiology. Heart and circulatory physiology.

[29]  E. Olson,et al.  CaMKIIδ Isoforms Differentially Affect Calcium Handling but Similarly Regulate HDAC/MEF2 Transcriptional Responses* , 2007, Journal of Biological Chemistry.

[30]  Teruo Hayashi,et al.  Sigma-1 Receptor Chaperones at the ER- Mitochondrion Interface Regulate Ca2+ Signaling and Cell Survival , 2007, Cell.

[31]  Hani N Sabbah,et al.  Chronic heart failure slows late sodium current in human and canine ventricular myocytes: Implications for repolarization variability , 2007, European journal of heart failure.

[32]  Donald M Bers,et al.  Role of Ca2+/calmodulin-dependent protein kinase (CaMK) in excitation-contraction coupling in the heart. , 2007, Cardiovascular research.

[33]  H. Krum,et al.  Drug discovery for heart failure: a new era or the end of the pipeline? , 2007, Nature Reviews Drug Discovery.

[34]  Stefan Wagner,et al.  Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels. , 2006, The Journal of clinical investigation.

[35]  Hani N Sabbah,et al.  Ranolazine Improves Abnormal Repolarization and Contraction in Left Ventricular Myocytes of Dogs with Heart Failure by Inhibiting Late Sodium Current , 2006, Journal of cardiovascular electrophysiology.

[36]  Nolwenn Le Meur,et al.  Human Atrial Ion Channel and Transporter Subunit Gene-Expression Remodeling Associated With Valvular Heart Disease and Atrial Fibrillation , 2005, Circulation.

[37]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[38]  J. Molkentin,et al.  Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. , 2004, Biochemical and biophysical research communications.

[39]  M. Hori,et al.  Prolonged Endoplasmic Reticulum Stress in Hypertrophic and Failing Heart After Aortic Constriction: Possible Contribution of Endoplasmic Reticulum Stress to Cardiac Myocyte Apoptosis , 2004, Circulation.

[40]  A. Marks,et al.  Novel therapeutic approaches for heart failure by normalizing calcium cycling , 2004, Nature Reviews Drug Discovery.

[41]  Stephan E. Lehnart,et al.  Ca2+/Calmodulin-Dependent Protein Kinase II Phosphorylation Regulates the Cardiac Ryanodine Receptor , 2004, Circulation research.

[42]  B. Chaitman.  Efficacy and Safety of a Metabolic Modulator Drug in Chronic Stable Angina: Review of Evidence from Clinical Trials , 2004, Journal of cardiovascular pharmacology and therapeutics.

[43]  Antonis A Armoundas,et al.  Role of Sodium-Calcium Exchanger in Modulating the Action Potential of Ventricular Myocytes From Normal and Failing Hearts , 2003, Circulation research.

[44]  Xiao-Ping Yang,et al.  Increased Systolic Performance With Diastolic Dysfunction in Adult Spontaneously Hypertensive Rats , 2003, Hypertension.

[45]  K. Maehara,et al.  Different Effects of Carvedilol, Metoprolol, and Propranolol on Left Ventricular Remodeling After Coronary Stenosis or After Permanent Coronary Occlusion in Rats , 2002, Circulation.

[46]  G. Cooper,et al.  Load Responsiveness of Protein Synthesis in Adult Mammalian Myocardium: Role of Cardiac Deformation Linked to Sodium Influx , 1989, Circulation research.

[47]  J. A. Wasserstrom,et al.  Intracellular Sodium and the Positive Inotropic Effect of Veratridine and Cardiac Glycoside in Sheep Purkinje Fibers , 1986, Circulation research.

[48]  C. Rapezzi,et al.  Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study , 2018, Circulation. Heart failure.

[49]  L. Maier,et al.  Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy. , 2016, Cardiovascular research.

[50]  Igor R Efimov,et al.  Remodeling of calcium handling in human heart failure. , 2012, Advances in experimental medicine and biology.

[51]  Teruo Hayashi,et al.  Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. , 2007, Cell.